Zenas BioPharma’s (ZBIO) Buy Rating Reaffirmed at HC Wainwright

Zenas BioPharma (NASDAQ:ZBIO)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $44.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 132.80% from the stock’s current price.

A number of other research analysts also recently commented on the stock. Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a report on Friday, March 27th. Guggenheim upped their price target on shares of Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, March 16th. Wall Street Zen downgraded shares of Zenas BioPharma from a “hold” rating to a “strong sell” rating in a research note on Saturday, March 21st. Finally, Zacks Research lowered shares of Zenas BioPharma from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 17th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $44.29.

Zenas BioPharma Price Performance

ZBIO stock opened at $18.90 on Friday. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -2.23 and a beta of -0.61. The company has a quick ratio of 5.61, a current ratio of 5.61 and a debt-to-equity ratio of 0.32. Zenas BioPharma has a 52-week low of $8.86 and a 52-week high of $44.60. The stock’s fifty day simple moving average is $21.36 and its 200-day simple moving average is $26.81.

Zenas BioPharma (NASDAQ:ZBIO) last released its earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same period last year, the business earned ($0.80) earnings per share. Equities research analysts expect that Zenas BioPharma will post -4.97 EPS for the current year.

Insider Activity

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. bought 35,000 shares of the business’s stock in a transaction dated Wednesday, April 29th. The shares were acquired at an average price of $17.62 per share, with a total value of $616,700.00. Following the purchase, the chief executive officer owned 1,786,039 shares in the company, valued at approximately $31,470,007.18. The trade was a 2.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Fairmount Funds Management Llc bought 150,000 shares of Zenas BioPharma stock in a transaction that occurred on Tuesday, March 31st. The shares were acquired at an average price of $20.00 per share, for a total transaction of $3,000,000.00. Following the acquisition, the director directly owned 2,359,025 shares in the company, valued at approximately $47,180,500. This represents a 6.79% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 213,768 shares of company stock valued at $4,137,398 in the last three months. Corporate insiders own 22.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. SR One Capital Management LP lifted its stake in shares of Zenas BioPharma by 2.6% during the fourth quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock worth $182,924,000 after purchasing an additional 126,315 shares in the last quarter. NEA Management Company LLC grew its stake in shares of Zenas BioPharma by 28.9% in the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after buying an additional 789,500 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Zenas BioPharma by 45.9% in the fourth quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after buying an additional 853,740 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Zenas BioPharma by 25.0% during the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after buying an additional 290,307 shares during the period. Finally, Polar Capital Holdings Plc purchased a new stake in shares of Zenas BioPharma during the 4th quarter valued at about $38,402,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.